Bausch + Lomb Corporation
BLCO | NYSE
$16.80
-$0.05 (-0.30%)
At close: Sep 21, 2026, 4:00 PM ET
$16.80
$0 (0.00%)
After-hours:
Sep 21, 2026, 5:05 PM ET
Company Profile
Bausch + Lomb Corporation is a leading global eye health company. Its operations are structured across three primary segments: Vision Care/Consumer Health, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health division offers a comprehensive portfolio of contact lenses, encompassing all wearing modalities from daily disposables to frequently replaced options. This segment also provides essential contact lens care products, over-the-counter eye drops, and nutritional supplements aimed at alleviating common eye conditions like allergies, conjunctivitis, and dry eye. Through its Ophthalmic Pharmaceuticals segment, the company develops and markets both proprietary and generic prescription medications. These pharmaceuticals are utilized for post-operative recovery and the treatment of various ocular diseases, such as glaucoma, ocular hypertension, and retinal disorders. Additionally, it supplies therapeutic contact lenses. The Surgical segment is dedicated to providing advanced tools and technologies for surgical interventions related to cataracts, as well as vitreous and retinal conditions. Its offerings include intraocular lenses (IOLs) with their delivery systems, phacoemulsification equipment, and a range of other specialized surgical instruments and devices. Founded in 1853, Bausch + Lomb is headquartered in Vaughan, Canada.
Key Executives
| Name | Position |
|---|---|
| Brenton L. Saunders | Chief Executive Officer & Director |
| A. Robert D. Bailey | Executive Vice President & Chief Legal Officer |
| Osama A. Eldessouky | Executive Vice President & Chief Financial Officer |
| Alan Waterhouse CPFA | Executive Vice President and Chief Supply Chain & Operations Officer |
| Andrew Stewart | President of Global Pharmaceuticals & International Consumer |
| Crawford | Chief Communications Officer |
| Frederick J. Munsch | Senior Vice President, Controller & Chief Accounting Officer |
| George Gadkowski | Vice President & Head of Investor Relations & Business Insights |
| Jonathon L. Kellerman | Chief Compliance Officer |
| Manisha A. Narasimhan | Chief Corporate Development & Digital Officer |
| Yehia Hashad | Executive Vice President of Research & Development and Chief Medical officer |
Bausch + Lomb Corporation
| Country | Canada |
| IPO Date | May 5, 2022 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 13,000 |
| CEO | Brenton L. Saunders |
Contact Details
520 Applewood Crescent Vaughan,
ON L4K 4B4 Canada
Stock Details
| Ticker Symbol | BLCO |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001860742 |
| CUSIP Number | 071705107 |
| ISIN Number | CA0717051076 |
| SIC Code | 3851 |
Recent News
- 8 days ago / zacks.comBLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser
- 11 days ago / businesswire.comBausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond Laser
- 28 days ago / zacks.comBausch + Lomb Advances Two First-in-Class Eye Health Therapies
- 28 days ago / seekingalpha.comBausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
- 28 days ago / marketbeat.comBausch + Lomb Advances Dry Eye Drug to Phase III as Pain Candidate Hits Phase Ib Goal
- 2 months ago / seekingalpha.comBausch + Lomb Corporation (BLCO) Q2 2026 Earnings Call Transcript
- 2 months ago / marketbeat.comBausch + Lomb Q2 Earnings Call Highlights
- 2 months ago / zacks.comBausch + Lomb (BLCO) Q2 Earnings Meet Estimates
- 2 months ago / zacks.comBausch + Lomb Launches EyeGility Inserter for enVista IOLs in the U.S.
- 2 months ago / businesswire.comBausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate
Add to Watchlist
Select watchlists to add or remove BLCO